Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
06/2003
06/19/2003CA2469589A1 Method of large scale production of hepatitis a virus
06/19/2003CA2469491A1 Composition for viral preservation
06/19/2003CA2469306A1 Methods and compositions for control of bone formation via modulation of sympathetic tone
06/19/2003CA2469274A1 Tumor antigens
06/19/2003CA2469266A1 The method of treating cancer
06/19/2003CA2469204A1 Prospective identification and characterization of breast cancer stem cells
06/19/2003CA2469161A1 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
06/19/2003CA2469049A1 Endogenous retrovirus polypeptides linked to oncogenic transformation
06/19/2003CA2469045A1 Methods of therapy for non-hodgkin's lymphoma
06/19/2003CA2468297A1 Method of purifying hepatitis a virus particles and vaccine preparation
06/19/2003CA2468266A1 Substituted bicyclic pyrimidinones as a mitotic kinesin ksp inhibitors
06/19/2003CA2467726A1 Mitotic kinesin inhibitors
06/19/2003CA2467722A1 Thienopyrimidinone derivatives as mitotic kinesin inhibitors
06/18/2003EP1319408A1 Remedies for heart failure
06/18/2003EP1319186A1 Prognostic indicator
06/18/2003EP1319184A2 Use of antibodies against specific mhc-peptide complexes
06/18/2003EP1319075A2 The c. albicans tec1 gene (catec1) and the coded tec1p protein
06/18/2003EP1319069A2 Compositions and methods for the therapy and diagnosis of lung cancer
06/18/2003EP1319066A2 Isolated human kinase proteins, nucleic acid molecules and uses thereof
06/18/2003EP1319025A2 Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse
06/18/2003EP1319020A2 VARIANTS OF THE MAJOR ALLERGEN Par j 2 OF Paritaria judaica
06/18/2003EP1319018A2 Influenza a virus haemagglutinin subtype h16 proteins and their encoding nucleic acid
06/18/2003EP1319017A2 Haemophilus influenzae basb202 polypeptide, production, vaccine and diagnostic use
06/18/2003EP1318836A2 Treatment of hyperproliferative diseases
06/18/2003EP1318835A1 Use of imidazoquinolinamines as adjuvants in dna vaccination
06/18/2003EP1318831A2 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism
06/18/2003EP1318830A2 Notch receptor agonists and uses
06/18/2003EP1318823A1 Immunomodulatory preparation
06/18/2003EP1151005B1 Peptide variants of the tumour marker muc1 and the use thereof
06/18/2003EP1009382B1 Oil in water emulsions containing saponins
06/18/2003EP0920623B1 Boron neutron capture therapy using pre-targeting methods
06/18/2003EP0638124B1 Oral infection of insect larvae with pre-occluded baculovirus particles
06/18/2003CN1425066A Novel stra6 polypeptides
06/18/2003CN1425062A Dioxygenases catalyzing asymetric cleavage of beta-carotene
06/18/2003CN1425027A HCV non-structural polypeptide
06/18/2003CN1424917A Recombinant envelope vaccine against flavivirus infection
06/18/2003CN1424110A Vaccine adjuvant against hepatitis B
06/18/2003CN1424109A Use of ginsenoside Rbl
06/18/2003CN1111540C Tandem synthetic HIV-1 peptides
06/18/2003CN1111429C Urease-based vaccine against HeIicobacter infection
06/17/2003US6579973 Compositions for the treatment and diagnosis of breast cancer and methods for their use
06/17/2003US6579972 An antibody having a specific binding affinity to a polypeptide of given amino acid sequence; can use in treating diabetes, skeletal muscle diseases, Alzheimer's disease, or peripheral neuropathies with an agonist or antagonist
06/17/2003US6579970 Specific octapeptides, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds and immune effector cells raised in response to presentation of these epitopes.
06/17/2003US6579969 Purified polypeptide of given amino acid sequence; serine/threonine kinase
06/17/2003US6579711 Lactic acid bacteria species
06/17/2003US6579700 Neuropeptide Y (NPY); isolated peptide of given amino acid sequence; may be useful in regulating central and peripheral nervous and endocrine systems
06/17/2003US6579691 DNA sequence encoding a neuronal protein kinase (NPK) which phosphorylates tau proteins as well as other microtubule associated proteins (MAPs) in positions crucial for the binding to microtubules, alzheimers disease, antitumor
06/17/2003US6579688 Stabilizing diluent for polypeptides and antigens
06/17/2003US6579684 Assay of YKL-40 as a marker for cancer
06/17/2003US6579683 A ligand which is a member of Ephrin family of Eph family receptor interactive protein has been shown to be expressed by arterial endothelial cells but not by venous endothelial cell, useful for distinguishing target artieris and veins
06/17/2003US6579528 Vaccines; genetically engineering
06/17/2003US6579527 Recombinant Pallas's cat FIV (FIV-Oma) virus, FIV-Oma3; vectors; antigens have broad specificity for immunization of cats; also use in diagnosis
06/17/2003US6579526 Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
06/17/2003US6579524 Polypeptide having amino acid sequence of C-terminal part of circumsporozoite protein of Plasmodium; oxidized cysteine residue pairs
06/17/2003US6578582 Method and apparatus using IDS™ for multi-agent therapy
06/17/2003CA2232410C Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
06/17/2003CA2129820C Dna sequences encoding novel growth/differentiation factors
06/17/2003CA2118816C Composition for introducing nucleic acid complexes into higher eucaryotic cells
06/17/2003CA2100462C Non-depleting cd4-specific monoclonal antibodies for the treatment of insulin-dependent diabetes mellitus (iddm)
06/17/2003CA2088163C Liposomes that provide thymic dependent help to weak vaccine antigens
06/17/2003CA2078605C Chicken anaemia agent vaccine
06/17/2003CA1341431C Immunotherapy for aids patients
06/13/2003WO2003047602A1 Immunostimulatory oligodeoxynucleotides
06/13/2003CA2452909A1 Immunostimulatory oligodeoxynucleotides
06/12/2003WO2003049117A2 Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
06/12/2003WO2003048780A2 Uses of aldose-1-epimerase (mutarotase) for diagnosis and therapy of inflammatory diseases and sepsis
06/12/2003WO2003048775A2 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
06/12/2003WO2003048729A2 Discovery of therapeutic products
06/12/2003WO2003048390A1 A process for the preparation of a non-toxic anthrax vaccine
06/12/2003WO2003048379A1 T-bet compositions and methods of use thereof
06/12/2003WO2003048371A2 Dna vaccine
06/12/2003WO2003048354A1 Protein-decomposing/eliminating enzyme and utilization thereof
06/12/2003WO2003048348A2 Production of viruses, viral isolates and vaccines
06/12/2003WO2003048337A2 Antibody to latent membrane proteins and uses thereof
06/12/2003WO2003048328A2 Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
06/12/2003WO2003048327A2 Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
06/12/2003WO2003048321A2 Hybrid antibodies
06/12/2003WO2003048304A2 ALLOIOCOCCUS OTITIDIS OPEN READING FRAMES (ORFs) ENCODING POLYPEPTIDE ANTIGENS, IMMUNOGENIC COMPOSITIONS AND USES THEREOF
06/12/2003WO2003048302A2 Identifying anti-tumor targets or agents by lipid raft immunization and proteomics
06/12/2003WO2003048301A2 Anti-hla-dr antibodies and the methods of using thereof
06/12/2003WO2003048299A2 Novel spore wall proteins and genes from microsporidia
06/12/2003WO2003048209A1 Bispecific anti-cd19 x anti-cd16 antibodies and uses thereof
06/12/2003WO2003048206A2 Growth hormone agonist peptides and their uses
06/12/2003WO2003048205A2 Novel proteins with il-6 inhibiting activity
06/12/2003WO2003048199A1 Cytotoxic protein and utilization thereof
06/12/2003WO2003048198A2 Polypeptides inducing apoptosis, polynucleotides encoding them and therapeutic uses thereof
06/12/2003WO2003048197A1 Production and of viruses, viral isolates and vaccines
06/12/2003WO2003048193A2 GIPs, A FAMILY OF POLYPEPTIDES WITH TRANSCRIPTION FACTOR ACTIVITY THAT INTERACT WITH GOODPASTURE ANTIGEN BINDING PROTEIN
06/12/2003WO2003048186A2 Surface simulation synthetic peptides useful in the treatment of hyper-variable viral pathogens
06/12/2003WO2003048184A2 Flavivirus ns1 subunit vaccine
06/12/2003WO2003047684A2 Method for intracellular modifications within living cells using pulsed electric fields
06/12/2003WO2003047633A2 Treatment of angiogenesis disorders using targeted nanoparticles
06/12/2003WO2003047623A1 Treatment of prostate cancer by inhibitors of ncam2
06/12/2003WO2003047619A2 Adjuvanted antigenic meningococcal compositions
06/12/2003WO2003047618A2 Immunotherapeutic methods and systems
06/12/2003WO2003047617A2 Vaccine
06/12/2003WO2003047611A2 Ptp10d, tec and edtp involved in triglycerid-metabolism
06/12/2003WO2003047606A2 Minor histocompatibility antigen ha-1: target antigen for immunotherapy of tumors
06/12/2003WO2003047586A1 Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
06/12/2003WO2003047577A2 Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses
1 ... 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 ... 1823